Patients are probably asking you about Deplin, or L-methylfolate, a version of folic acid that is being marketed by Pamlab as an adjunctive treatment for depression.
Read More
Nuedexta is a combination of dextromethorphan (DM) and quinidine sulfate. You might reasonably ask why these two agents would have ever been considered as a treatment for PBA.
Read More
Defining CAM is challenging. One of the things that makes it so hard to have a concrete discussion on CAM is that it means different things to different people.
Read More
Common sense dictates that genetic predispositions probably interact with life stressors to influence our mental health. Plenty of research has been published to evaluate whether this is actually true, but findings have been mixed.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
